Insight on Pharmaceuticals and Healthcare

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Report
Report

Biotech Company Outlook to 2016

Analysis of the outlook for Datamonitor's Biotech peer set of companies through to 2016, identifying key strategic themes and looking at sales performance by company, lifecycle stage, therapy area, and molecule type

Published By Datamonitor
18 Nov 2011 $2800
Buy
Report
Report

Boehringer Ingelheim: Company Analysis

Analysis of Boehringer Ingelheim's corporate strategy, marketed portfolio, pipeline potential and financial position in 2011 and to 2017

Published By Datamonitor
26 Oct 2012 $2800
Buy
Report
Report

Branded Prescription Pharmaceutical Sales Outlook to 2016

An analysis of global sales forecasts for the Branded PharmaVitae Universe during 2011–16.

Published By Datamonitor
03 Feb 2012 $2800
Buy
Report
Report

Brazil Pharmaceutical Market Overview - Expanding healthcare access drives double-digit sales growth

Overview of the pharmaceutical market in Brazil including socioeconomic and demographic trends, regulatory issues, generics and biosimilars analysis and pharmaceutical company infrastructure analysis.

Published By Datamonitor
26 Aug 2010 $7600
Buy
Report
Report

Brazil Pharmaceutical Market Overview – Strong market growth continues, but regulatory risks increase

Overview of the pharmaceutical market in Brazil including socioeconomic and demographic trends, regulatory issues, generics and biosimilars analysis, and pharmaceutical market and pharmaceutical company infrastructure analysis.

Published By Datamonitor
21 Sep 2012 $2800
Buy
Report
Report

BRIC: Pricing, Reimbursement, and Regulatory Update

Datamonitor’s report BRIC: Pricing, Reimbursement, and Regulatory Update provides an update of changes to pricing, reimbursement and regulation in Brazil, Russia, India and China during the first half of 2011.

Published By Datamonitor
08 Sep 2011 $1520
Buy
Brief
Brief

Brief: Hepatitis C/AASLD 2010

This brief is an overview of the HCV highlights from the 2010 American Association of the Study of Liver Disease meeting. It discusses pivotal data for telaprevir and boceprevir, results for TMC435 and data from interferon-sparing studies.

Published By Datamonitor
13 Dec 2010 $400
Buy
Report
Report

Bristol-Myers Squibb Co.: Company Analysis

Analysis of BMS's corporate strategy, marketed portfolio, pipeline potential and financial position in 2011 and to 2017

Published By Datamonitor
08 Aug 2012 $2800
Buy
Report
Report

Bydureon FDA Approval: Physician Opinion

Physician survey of 84 endocrinologists and primary care physicians on their impressions and expected use of Amylin’s and Alkermes’s Bydureon (once-weekly exenatide)

Published By Datamonitor
24 Feb 2012 $2800
Buy
Report
Report

Canada: Generics and Biosimilars Overview

Overview of the generics and biosimilars landscape including, regulatory issues, drivers and resistors to uptake, level of penetration, and key players operating in the market.

Published By Datamonitor
03 Nov 2011 $1520
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.